The primary therapeutic application of Vazaprostan (Alprostadil) is generally focused on providing supportive therapy in advanced stages of peripheral vascular disease. Clinical application in this area is relevant to managing healing and limb preservation in patients with advanced arterial blockages.

This medication is commonly used to help manage severe symptoms associated with conditions like Critical Limb Ischemia (CLI), advanced Chronic Arterial Occlusive Disease (CAOD), and certain cases of Thromboangiitis Obliterans (Buerger’s disease). Limb preservation may be a central focus of this therapy, which supports threatened tissues.

Relief and Symptom Management

The treatment is relevant for easing symptoms related to physical discomfort, such as intractable ischemic rest pain, and symptoms that create noticeable physiological strain, particularly ischemic ulcers, trophic lesions, and minor tissue necrosis on the limbs. The therapy may contribute to improved comfort and support the body’s healing process, assisting with the management of chronic wounds during difficult episodes.

---

Quick Fact: Relief for Ischemic Symptoms

• Primary Focus: Critical Limb Ischemia (CLI).
• Symptom Relief: Is used for managing intractable rest pain and supports the handling of ischemic ulcers.
• Patient Benefit: Contributes to limb preservation goals and helps improve comfort during symptomatic periods.

Regulatory References

1. ClinicalTrials.gov, a service of the NIH

Who Can and Cannot Use Vazaprostan (Iloprost)

Official regulatory documents define specific populations and conditions that restrict or prohibit the use of the drug containing the active substance Iloprost.

Contraindicated Populations (Must Not Use)

Use of the medicine is strictly contraindicated in patients with the following conditions:

• Severe Unstable Heart Conditions: Including severe coronary heart disease, unstable angina, myocardial infarction within the last six months, or severe cardiac arrhythmias.
• Hemorrhage Risk: Any condition that would increase the risk of bleeding due to the drug's effect on platelets, such as active peptic ulcers, trauma, or intracranial hemorrhage.
• Pulmonary Veno-Occlusive Disease (PVOD).
• Hypersensitivity to iloprost or any excipients.

Populations Requiring Restricted or Conditional Use

• Low Blood Pressure (Hypotension): The medicine must not be initiated if the patient's systolic blood pressure is less than 85 mmHg.
• Organ Function Impairment: Patients with moderate or severe hepatic impairment or renal failure requiring dialysis must receive a reduced and carefully monitored starting dose.
• Age: Safety and effectiveness in the pediatric population (children and adolescents) have not been established.
• Pregnancy and Lactation: Use is generally contraindicated during pregnancy, and women must use effective contraception. It is also contraindicated for women who are breastfeeding.

Interactions with other medicines and products

The official interaction profile for Vazaprostan is defined primarily by Pharmacodynamic (PD) interactions that result from its core effects as a potent vasodilator and inhibitor of platelet aggregation.

Product Categories with Documented Interactions	Interaction Basis and Outcome
Anticoagulants (e.g., Heparin, Warfarin), Platelet Aggregation Inhibitors	PD enhancement of anti-thrombotic effects, officially resulting in an increased risk of bleeding.
Other Vasodilative Agents, Antihypertensive Drugs	PD enhancement, leading to an officially documented increased risk of hypotensive effects.
Sympathomimetics	Pharmacodynamic interaction that may officially reduce the effect of Vazaprostan.

Timing and Preparation Constraints

Regulatory documentation specifies constraints on the preparation and administration of Vazaprostan solution. The product must not be mixed or coadministered with any other medicinal products in the same infusion solution. This is a mandatory restriction due to the absence of formal compatibility studies with other substances.

Pharmacokinetic and Contraindication Profile

Regulatory labels state that the potential for pharmacokinetic (PK) drug-drug interactions (such as those mediated by CYP enzymes or transport proteins) has not been formally studied or documented. Furthermore, no combinations are formally listed as contraindicated due solely to a drug-drug interaction for the intravenous infusion route of this medicine. There are no explicitly documented interactions with food, alcohol, or herbal products in the official prescribing information.

Activation of the Vascular Relaxation Signal

Vazaprostan (Alprostadil) functions as a direct agonist, specifically targeting and activating the Prostaglandin EP2 receptors found on the smooth muscle cells lining peripheral blood vessels. This receptor engagement rapidly stimulates the enzyme Adenylate Cyclase, causing a significant increase in the intracellular second messenger cAMP. This molecular cascade is critical because it ultimately leads to a reduction in free cellular calcium, which is the immediate cause of vascular smooth muscle relaxation and resulting pronounced vasodilation.

Dual Modulation of Flow Dynamics

The cAMP signaling pathway triggered by the drug is leveraged across two key physiological processes. Beyond causing vessel widening, the rise in cAMP also occurs in blood platelets, where it acts to inhibit their activation and aggregation. This dual effect of pronounced peripheral vasodilation combined with the inhibition of thrombotic activity synergistically reduces vascular resistance and maintains the overall fluidity of blood flow through the microvasculature.

Administration Scope

The use of Vazaprostan is strictly governed by detailed instructions, as it is a lyophilized powder requiring specialized preparation and administration via infusion. The medicine is labeled for administration through either Intravenous (IV) Infusion or Intra-arterial (IA) Infusion.

Instruction Domain	Official Guideline (Strictly Label-Based)
Dosing Schedule	IV: Typically 40 mcg per administration. IA: Starting dose of 10 mcg, which may be raised to 20 mcg (maximum) if necessary.
Frequency and Duration	IV: Administered twice daily (b.i.d.), with each infusion lasting 2 hours. IA: Administered once daily over approximately 1 hour.
Preparation Requirements	Requires mandatory reconstitution of the powder followed by dilution into an isotonic carrier solution (e.g., sodium chloride or glucose solution).
Special Populations	Dose adjustments are typically necessary for patients diagnosed with severe renal impairment due to the metabolic elimination route.

Resulting Procedural Structure

The official instructions define a three-stage procedural structure for each administration. First, the powder must be dissolved, and the resulting solution must then be diluted into the specified carrier fluid volume. The medicine must be administered using a controlled infusion pump by medically trained personnel, ensuring the dose is delivered precisely over the mandated time period (e.g., two hours for the IV dose). The standard course of therapy is time-bound, typically structured for a period of 3 weeks and not recommended to exceed 4 weeks.

Research Evidence / Overview of Studies for Vazaprostan

Evidence for use in Advanced Peripheral Arterial Disease (PAOD Stage IV / CLI)

Vazaprostan (Alprostadil) was studied in adult patients with severe peripheral arterial disease (PAD), specifically Critical Limb Ischemia (CLI). The structure of the research includes randomized controlled trials (RCTs), which compared the medicine to an inactive substance (placebo), and systematic reviews that combined data from many studies.

In these research scenarios, researchers examined patient outcomes related to the frequency of major amputation, the status of ischemic ulcers and necrotic tissue, and changes in the severity of rest pain. While some meta-analyses reported patterns related to the status of ulcers and changes in rest pain intensity, findings were mixed across specific large-scale randomized trials. For instance, one major study reported that the research examined did not demonstrate a difference compared to placebo based on the primary study goals. The evidence contributes to understanding symptom patterns, but the data show patterns that vary, and the results reflect the specific conditions under which they were conducted.

Research on Thromboangiitis Obliterans (Buerger’s Disease)

For the rare condition known as Thromboangiitis Obliterans, the structure of the evidence base is distinct from that for general PAD. Studies are primarily comprised of comparative reviews and observational settings rather than large-scale randomized trials. Research examined outcomes related to physical discomfort, specifically changes in rest pain intensity and the status of ischemic ulcers in patients.

Follow-up Duration and Long-Term Data

For most key trials, the primary outcomes related to the status of ulcers and amputation rates were assessed at intermediate follow-up periods, usually spanning between 12 and 24 weeks after the end of the treatment course. There is limited information for long-term outcomes beyond these intermediate time points, meaning the maintenance of ulcer status or continued limb salvage are not fully established from the main RCTs.

Consistency and Uncertainty in the Evidence Base

The overall quality of the evidence for prostanoids in CLI, as assessed by major reviews, is often described as moderate to low, and certainty remains low for several major outcomes. Research highlights what is known—that studies describe group patterns—and what is still uncertain—that significant heterogeneity and modest sample sizes limit the ability to draw definitive conclusions across all patient groups.

Key Studies & References Prostanoids for critical limb ischaemia (Cochrane Systematic Review, 2018 update)

How to Store and Dispose of Vazaprostan

The storage of Vazaprostan (Alprostadil powder for infusion) is strictly defined by regulatory labeling to maintain stability. Unopened vials often require storage in a refrigerator at 2 C to 8 C or at controlled room temperature, but must not be frozen.

Stability and Handling

The medicine is a single-use vial, and the reconstituted solution should be used immediately. Stability limits the use of the prepared solution to within 24 hours at a maximum, and the product must be protected from bright light during preparation. Keep the medicine out of the sight and reach of children.

Disposal Requirements

Any unused portion of the solution must be thrown out. Used needles and syringes must be placed immediately into an FDA-cleared sharps disposal container and disposed of in accordance with local regulations.